Patient number/age
|
Previous treatment
|
EE2 response/biopsy site
|
---|
| |
LHRHa
|
LHRHa
| |
LHRHa
| | | | | | | | | | | | | | |
1
| |
+ Tam
|
+ ANA
| |
+ L
| |
TS-1
|
VNR
| |
PTX
| |
E
| |
EE2
| |
L
|
EE2
| |
| |
10m
|
12m
| |
3m
| |
12m
|
21m
| |
3m
| |
4m
| |
14m
| |
5m
| | |
Responder liver, local
|
59
| | | | | | | | | | | | |
^
| |
^
| | | |
| | | | | | | | | | | |
B
| |
A
| | | |
2
| | |
TS-1 +
| | | | | | | | | | | | | | | |
Responder lymph node
|
|
DTX
|
ANA
| |
E
| |
EC
|
DTX
| |
XC
| |
L
| |
EE2
| |
L
|
EE2
| |
|
15m
|
13m
| |
5m
| |
13m
|
24m
| |
6m
| |
7m
| |
14m
| |
6m
| | |
62
| | | | | | | | | | | | |
^
| |
^
| | | |
| | | | | | | | | | | |
B
| |
A
| | | |
3
| | | | | | | | | | | | | | | | |
H +
| |
Non-responder local
|
| | | | | |
FEC
|
XT
| |
ANA
| |
E
| |
EE2
| |
FUL
|
PTX
| |
| | | | | | |
3m
|
12m
| |
8m
| |
2m
| |
4m
| |
3m
| | |
56
| | | | | |
^
| | |
^
| |
^
| | | |
^
| | |
^
|
| | | | |
B
| | |
B
| |
B
| | | |
A
| | |
A
|
| |
E
|
MPA
| |
Tam
| |
L
|
TS-1
| |
ANA
| |
Tor
| |
EE2
| |
L
| | |
Responder skin
|
4
| | |
8m
| |
9m
| |
2m
|
13m
| |
8m
| |
2m
| |
12m
| | | | |
64
| | | | | | | | |
^
| |
^
| | |
^
|
^
| | | |
| | | | | | | |
B
| |
B
| | |
D
|
A
| | | |
| |
AC
|
H
| |
L
| |
Tor
|
E+H
| |
PTX
| |
L
| |
EE2
| |
FuL
| | |
Responder local
|
5
| |
8m
|
7m
| |
8m
| |
6m
|
1m
| |
4m
| |
3m
| |
8m
| | | | |
58
| | | |
^
|
^
|
^
|
^
|
^
| | | | |
^
|
^
|
^
| | | |
| | |
B
|
B
|
B
|
B
|
B
| | | | |
B
|
D
|
A
| | | |
|
L
|
ANA
|
XC
| |
TS-1
| |
ANA
|
Tor
| |
PTX
| |
ANA
| |
EE2
| | | | |
Responder local
|
6
|
16m
|
3m
|
9m
| |
3m
| |
2m
|
7m
| |
11m
| |
3m
| |
14m
--
| | | | |
83
| | | | | | | | | | | | |
^
| |
^
| | | |
| | | | | | | | | | | |
B
| |
B
| | | |
- ^: the time point when tissue was obtained.
- B: before EE2 treatment D: During EE2 treatment; A: After EE2 treatment.
- Sample shown in bold letter were used in this study.
-
Abbreviations: ANA: anastozole; AC: doxorubicine + cyclophosphamide; DTX: docetaxel; E: exemestane; EC: Epirubicine + cydophoshamide; FEC: cydoshsphamide + epirubine+5-FU; FUL: fulvestrant; H: herceptine; L: letrozole; MPA: medroxyprogesterone; PTX: paclitaxel; Tam: tamoxifen; Tor: toremifeme; VNR: vinorelubin; XC: capecitabine + cyclophosphamide; XT: capecitabine + docetaxel.